Literature DB >> 12883981

The use of steroid-sparing agents in steroid-sensitive nephrotic syndrome.

Asiri S Abeyagunawardena1, Michael J Dillon, Lesley Rees, William van't Hoff, Richard S Trompeter.   

Abstract

Childhood nephrotic syndrome (NS) is frequently characterized by a relapsing course. There is no uniform agreement about the precise stage at which a steroid-sparing agent should be introduced to control the disease. In order to evaluate the treatment strategies and outcome of steroid-sensitive NS over the last 2 decades, a retrospective notes review was undertaken in a cohort of children treated at Great Ormond Street Children's Hospital between 1980 and 2000. From a population of 863 children with NS referred, 509 had frequently relapsing or steroid-dependent disease and 261 children received at least one steroid-sparing agent. Cyclophosphamide was the first choice in 178 patients and in 114 no further steroid-sparing agent was needed. Levamisole was prescribed as the first steroid-sparing agent for 65 children and disease control was achieved in 30%. Cyclosporin A was prescribed in 61 children and sustained remission was induced in 69%. It is concluded that cyclophosphamide is a potent agent in inducing sustained remission in steroid-sensitive NS. Levamisole and cyclosporin A have emerged as attractive steroid-sparing agents. Complications and major side effects of treatment are infrequent but occasionally fatal.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12883981     DOI: 10.1007/s00467-003-1216-z

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  32 in total

Review 1.  Does it make sense to administer albumin to the patient with nephrotic oedema?

Authors:  E J Dorhout Mees
Journal:  Nephrol Dial Transplant       Date:  1996-07       Impact factor: 5.992

2.  Protracted levamisole in children with frequent-relapse nephrotic syndrome.

Authors:  F Ginevri; A Trivelli; M R Ciardi; G M Ghiggeri; F Parfumo; R Gusmano
Journal:  Pediatr Nephrol       Date:  1996-08       Impact factor: 3.714

3.  Liver toxicity in a nephrotic patient treated with levamisole.

Authors:  D T Bulugahapitiya
Journal:  Arch Dis Child       Date:  1997-03       Impact factor: 3.791

4.  Primary and secondary abnormalities of T cell subpopulations.

Authors:  R S Trompeter; L Layward; A R Hayward
Journal:  Clin Exp Immunol       Date:  1978-12       Impact factor: 4.330

Review 5.  Consensus statement on management and audit potential for steroid responsive nephrotic syndrome. Report of a Workshop by the British Association for Paediatric Nephrology and Research Unit, Royal College of Physicians.

Authors: 
Journal:  Arch Dis Child       Date:  1994-02       Impact factor: 3.791

6.  Pathogenesis of lipoid nephrosis: a disorder of T-cell function.

Authors:  R J Shalhoub
Journal:  Lancet       Date:  1974-09-07       Impact factor: 79.321

7.  Levamisole in steroid-sensitive nephrotic syndrome children with steroid-dependency and/or frequent relapses.

Authors:  L S Fu; C S Chi
Journal:  Acta Paediatr Taiwan       Date:  2000 Mar-Apr

8.  Early identification of frequent relapsers among children with minimal change nephrotic syndrome. A report of the International Study of Kidney Disease in Children.

Authors: 
Journal:  J Pediatr       Date:  1982-10       Impact factor: 4.406

9.  Cyclophosphamide treatment in steroid-sensitive nephrotic syndrome of childhood.

Authors:  T M Barratt; A Bercowsky; S G Osofsky; J F Soothill
Journal:  Lancet       Date:  1975-01-11       Impact factor: 79.321

10.  Lymphocyte subpopulations, interleukin-2 and interleukin-2 receptor expression in childhood nephrotic syndrome.

Authors:  S A Hulton; V Shah; M R Byrne; G Morgan; T M Barratt; M J Dillon
Journal:  Pediatr Nephrol       Date:  1994-04       Impact factor: 3.714

View more
  15 in total

1.  Population pharmacokinetics of levamisole in children with steroid-sensitive nephrotic syndrome.

Authors:  A R Kreeftmeijer-Vegter; T P C Dorlo; M P Gruppen; A de Boer; P J de Vries
Journal:  Br J Clin Pharmacol       Date:  2015-06-05       Impact factor: 4.335

2.  Short courses of daily prednisolone during upper respiratory tract infections reduce relapse frequency in childhood nephrotic syndrome.

Authors:  Asiri S Abeyagunawardena; R S Thalgahagoda; Pathum V Dissanayake; Shamali Abeyagunawardena; Y A Illangasekera; Umeshi I Karunadasa; Richard S Trompeter
Journal:  Pediatr Nephrol       Date:  2017-03-24       Impact factor: 3.714

Review 3.  Treatment of steroid sensitive nephrotic syndrome.

Authors:  A S Abeyagunawardena
Journal:  Indian J Pediatr       Date:  2005-09       Impact factor: 1.967

4.  Long-term results of two unconventional agents in steroid-dependent nephrotic children.

Authors:  Ahmed Farouk Donia; Hesham Mohamed Ammar; Amgad El-Baz El-Agroudy; Fatma El-Husseini Moustafa; Mohamed Abdel-Kader Sobh
Journal:  Pediatr Nephrol       Date:  2005-07-27       Impact factor: 3.714

5.  Short- and long-term efficacy of levamisole in children with steroid-sensitive nephrotic syndrome.

Authors:  Ahmet Taner Elmas; Yılmaz Tabel; Ozlem Nalbantoğlu Elmas
Journal:  Int Urol Nephrol       Date:  2012-07-24       Impact factor: 2.370

6.  Adrenocortical suppression increases the risk of relapse in nephrotic syndrome.

Authors:  Asiri S Abeyagunawardena; Peter Hindmarsh; Richard S Trompeter
Journal:  Arch Dis Child       Date:  2007-02-06       Impact factor: 3.791

Review 7.  Levamisole in steroid-sensitive nephrotic syndrome of childhood: the lost paradise?

Authors:  J C Davin; M P Merkus
Journal:  Pediatr Nephrol       Date:  2004-09-17       Impact factor: 3.714

8.  Mycophenolate mofetil in steroid-dependent idiopathic nephrotic syndrome.

Authors:  Laurène Dehoux; Julien Hogan; Claire Dossier; Marc Fila; Olivier Niel; Anne Maisin; Marie Alice Macher; Thérésa Kwon; Véronique Baudouin; Georges Deschênes
Journal:  Pediatr Nephrol       Date:  2016-06-04       Impact factor: 3.714

9.  Management patterns of childhood-onset nephrotic syndrome.

Authors:  Nathaniel MacHardy; Paul V Miles; Susan F Massengill; William E Smoyer; John D Mahan; Larry Greenbaum; Sara Massie; Lynne Yao; Shashi Nagaraj; Jen-Jar Lin; Delbert Wigfall; Howard Trachtman; Yichun Hu; Debbie S Gipson
Journal:  Pediatr Nephrol       Date:  2009-08-12       Impact factor: 3.714

10.  Long-term follow-up after cyclophosphamide and cyclosporine-A therapy in steroid-dependent and -resistant nephrotic syndrome.

Authors:  Viktória Sümegi; Ibolya Haszon; Csaba Bereczki; Ferenc Papp; Sándor Túri
Journal:  Pediatr Nephrol       Date:  2008-03-07       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.